Activity of temocillin against third-generation cephalosporin-resistant *Escherichia coli* and *Klebsiella pneumoniae* bloodstream isolates from a clinical trial

Adam G. Stewart 1,2,3*, Andrew Henderson1,4, Michelle J. Bauer1, David L. Paterson 1,2 and Patrick N. A. Harris 1,3

1Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Royal Brisbane and Women's Hospital Campus, Brisbane, Australia; 2Department of Infectious Diseases, Royal Brisbane and Women's Hospital, Brisbane, Australia; 3Central Microbiology, Pathology Queensland, Royal Brisbane and Women's Hospital, Brisbane, Australia; 4Infection Management Services, Princess Alexandra Hospital, Brisbane, QLD, Australia

*Corresponding author. E-mail: adam.stewart@uq.edu.au

Received 16 September 2021; accepted 30 November 2021

Background: Extended spectrum β-lactamase (ESBL) and AmpC-producing Gram-negative bacilli contribute significantly to the antimicrobial resistance (AMR) burden worldwide. Temocillin is an intravenous semisynthetic antibiotic that is stable to hydrolysis by ESBLs and AmpC. Temocillin may be a treatment option for serious infections due to these organisms.

Methods: Third-generation cephalosporin-resistant *Escherichia coli* and *Klebsiella pneumoniae* isolates from the MERINO trial were collected. The majority originated from the urinary tract. Isolates had previously undergone whole genome sequencing (WGS) to identify antimicrobial resistance genes. Temocillin minimum inhibitory concentration (MIC) values were determined by broth microdilution (BMD) with a concentration range of 2 to 128 mg/L. A recent EUCAST guideline has recommended clinical breakpoints for urinary *E. coli*, *Klebsiella* spp. (except *K. aerogenes*) and *Proteus mirabilis* (resistant ≥16 mg/L).

Results: 317 index bloodstream isolates (275 *E. coli* and 42 *K. pneumoniae*) were used. The frequency of β-lactamases among isolates was: CTX-M-15 (56%), OXA-1 (31%), CTX-M-27 (14%), CTX-M-14 (12%) and CMY-2 (8%). Overall, 95% of isolates were susceptible, increased exposure according to EUCAST clinical breakpoints v11.0. Summary MIC values were obtained: MIC50 was 8 mg/L and MIC90 was 16 mg/L (range 2 to 128 mg/L) and did not differ markedly between species. Higher MIC values were seen among isolates that produced more than one β-lactamase but this did not appear to be specific to a single β-lactamase.

Conclusions: Temocillin demonstrated favourable in vitro activity against ceftriaxone-resistant Enterobacterales bloodstream isolates and may be a suitable agent to be trialled for treatment of serious infections due to these organisms.

Introduction

β-Lactamase enzymes produced by Gram-negative bacilli (GNB) are a common mechanism of antimicrobial resistance (AMR).1 Extended-spectrum β-lactamasises (ESBLs) and AmpC β-lactamases are capable of hydrolysing commonly used broad-spectrum antibiotics such as ceftriaxone, cefotaxime and ceftazidime.1 Carbapenems are considered the first-line treatment option for severe infections due to ESBL- and AmpC-producing Enterobacterales. In no observational study has the outcome of serious infections for ESBL or AmpC producers treated with carbapenems been significantly surpassed by any other agents.2–4 Moreover, a landmark clinical trial comparing piperacillin/tazobactam with meropenem in the treatment of bloodstream infection due to ESBL-producing *Escherichia coli* and *Klebsiella pneumoniae* showed that piperacillin/tazobactam was not non-inferior to meropenem with respect to 30 day all-cause mortality.5 Widespread use of carbapenem antibiotics may lead to a rising incidence of carbapenem-resistant GNB.6 Availability of a carbapenem-sparing antimicrobial for the treatment of ESBL and AmpC producers would be of considerable value in halting the emergence of carbapenem resistance.

© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Temocillin is a semisynthetic 6-α-methoxypenicillin antibiotic, derived from ticarcillin, developed in the 1980s and available for parenteral administration. It demonstrates stability against β-lactamases including extended-spectrum SHV/TEM variants and CTX-M. This property has renewed the interest in this antimicrobial as a potential carbapenem-sparing therapy. Temocillin is currently registered for use in several European countries but is yet to be introduced in Australia or the United States. Recent changes to temocillin clinical breakpoints have been proposed by EUCAST. Here we assess the in vitro activity of temocillin against third-generation cephalosporin-resistant E. coli and K. pneumoniae bloodstream isolates obtained from a clinical trial.

Materials and methods

Bacterial isolates

The MERINO trial recruited patients with bloodstream infection due to third-generation cephalosporin non-susceptible E. coli and K. pneumoniae in nine countries from February 2014 to July 2017. All index blood culture isolates from patients meeting the inclusion criteria who consented to participate in the study were stored at the recruiting site laboratory at −80°C and later shipped to the coordinating laboratory in Queensland, Australia (University of Queensland Centre for Clinical Research). Stored isolates had previously undergone whole genome sequencing (WGS) to detect antimicrobial resistance genes. Each isolate was subjected to broth microdilution (BMD) testing for temocillin minimum inhibitory concentration (MIC) determination.

BMD preparation

BMD was performed according to ISO 20776-1 for non-fastidious organisms in unsupplemented Mueller-Hinton broth. Custom-made Sensititre plates sourced from Thermo Fisher Scientific were used and incorporated temocillin with a concentration range from 2 to 128 mg/L. This range was chosen to include the EUCAST breakpoint for E. coli and Klebsiella spp. (except K. aerogenes) of urinary origin; resistant >16 mg/L. The wild-type population for these species have been placed in the intermediate group (1–16 mg/L) with 16 mg/L representing the epidemiological cut-off values (ECOFFs) for most target species. This implies that EUCAST do not specify a ‘Susceptible’ category and emphasizes the use of high dose temocillin (2 g q8h) for urinary tract isolates with MIC <16 mg/L. Prepared antibiotic was dispensed into custom made Sensititre labelled 96-well plates (ThermoScientific, 262162) which were inoculated. Escherichia coli ATCC 25922, target MIC 16 mg/L was used to check the performance of each batch of trays. Test and reference isolates were stored in brain heart infusion (BHI) broth (BD, Bacto 237500) containing 30% glycerol (Chem-Supply, 25922, target MIC 16 mg/L) were inoculated. Each well containing antibiotic was inoculated with 50 µL of broth (5 x 10⁵ cfu/mL). Purity and colony count checks were also performed.

Results

A total of 317 bloodstream isolates (275 E. coli and 42 K. pneumoniae) from the MERINO trial were collected and had their temocillin MIC determined by BMD. The most frequent β-lactamase types observed among isolates included CTX-M-15 (178/317, 56%), OXA-1 (98/317, 31%), CTX-M-27 (43/317, 14%), CTX-M-14 (37/317, 12%) and CMY-2 (24/317, 8%) (Tables 1 and 2). Overall, 95% of isolates had MIC values ≤16 mg/L, thus falling into the susceptible, increased exposure ranges according to EUCAST. Summary MIC values were obtained: MIC₅₀ was 8 mg/L and MIC₉₀ was 16 mg/L (range ≤2 to ≥128 mg/L). K. pneumoniae isolates appeared to have lower MIC values when compared with E. coli (MIC₅₀ values 4 and 8 mg/L, respectively). Interestingly, similar MIC values were seen among isolates producing ESBLs and AmpC β-lactamases (Figure 1). Producing a combination of β-lactamases, whether ESBL, AmpC or narrow-spectrum OXA, conferred higher temocillin MIC values. In particular, E. coli isolates that co-produced CTX-M type and CMY β-lactamases had high temocillin MIC values (Table 1). The MIC values for all the plates testing ATCC strains fell within acceptable ranges. Purity and colony count checks demonstrated pure growth and colony counts ranging from 1–9 colonies.

Discussion

Overall, temocillin demonstrated favourable in vitro potency against ESBL-, AmpC- and narrow-spectrum OXA-producing E. coli and K. pneumoniae. Of note, higher temocillin MICs were observed among isolates harbouring multiple β-lactamases (e.g. ESBL and AmpC). The presence of a specific β-lactamase did not appear to directly influence the MIC. For example, the addition of narrow-spectrum OXA to CTX-M-type β-lactamase did not appear to affect the MIC. Similarly, those isolates harbouring only AmpC β-lactamases did not have higher MIC values when compared with those with only CTX-M-type β-lactamases. The EUCAST breakpoint tables v11.0 (January 2021) have incorporated novel species-specific [E. coli, Klebsiella spp. (excluding K. aerogenes), and P. mirabilis] MIC breakpoints for temocillin: S ≤0.001, R ≥16 mg/L. EUCAST have stated that having an ‘R’ breakpoint below 16 mg/L would split the wild-type of the relevant species that are believed to be good targets for temocillin. Temocillin dosing of 2 g q8h for urinary isolates with an MIC of ≤16 mg/L is recommended. 95% of all isolates tested in our study had MICs below the EUCAST clinical breakpoint for resistance. Previously, the British Society of Antimicrobial Chemotherapy (BSAC) guidelines defined temocillin MIC breakpoints for Enterobacteriaceae as susceptible if ≤8 mg/L in systemic infections and ≤32 mg/L in urinary tract infections. Under those guidelines, 81% and 99% of our tested isolates would have been regarded as susceptible, respectively. In vitro activity of temocillin against MDR GNB has been examined in different settings worldwide. Among 177 ESBL-producing Enterobacteriales from Poland, 62% and 94% were susceptible according to BSAC systemic (≤8 mg/L) and urinary tract infection (UTI) (≤32 mg/L) breakpoints, respectively; MIC₅₀ and MIC₉₀ values were 8 mg/L and 32 mg/L, respectively. Another study examined 118 ESBL producers from Hong Kong and demonstrated susceptibility rates of 84% and 100%, respectively. Another study from England tested temocillin against 846 ESBL- and AmpC-producing Enterobacteriales and showed susceptibility rates (systemic and UTI) of 63% and 99% for ESBL producers, and 67% and 99% for AmpC producers. A Norwegian study looked at 105 ESBL-producing E. coli and showed rates of 71% and 100%. Interestingly, one study demonstrated reduced susceptibility to temocillin among AmpC producers when compared with ESBL-producing Enterobacteriales. That same study demonstrated a correlation between the rate of temocillin resistance and the number of β-lactams without in vitro activity. The mechanisms of resistance to temocillin in Enterobacteriales are largely unknown. Molecular studies on temocillin resistance mechanisms in
### Table 1. Temocillin MIC frequency distribution for 275 E. coli bloodstream isolates according to β-lactamase type

| Organism characteristics | Number of isolates with MIC (mg/L): ≤2 | 4 | 8 | 16 | 32 | 64 | ≥128 | Total no. | Susceptible, increased exposure (%) by EUCAST clinical breakpoint |
|--------------------------|----------------------------------------|---|---|---|----|----|------|-----------|---------------------------------------------------------------|
| All organisms            | 9 | 48 | 162 | 42 | 10 | 3 | 1 | 275 | 95 |
| No ESBL, AmpC or narrow-spectrum OXA ESBL only (n = 149) | 3 | 6 | 1 | | | | 10 | 100 |
| CTX-M-3                  | 2 | | | | | | | | |
| CTX-M-14                 | | | | | | | | | |
| CTX-M-15                 | | | | | | | | | |
| CTX-M-24                 | | | | | | | | | |
| CTX-M-27                 | | | | | | | | | |
| CTX-M-55                 | | | | | | | | | |
| CTX-M-134                | | | | | | | | | |
| CTX-M-174                | | | | | | | | | |
| Narrow-spectrum OXA only (n = 1) | | | | | | | | | |
| OXA-1                    | | | | | | | | | |
| AmpC only (n = 27)       | | | | | | | | | |
| CMY-2                    | 4 | 14 | 2 | 1 | | | | 21 | 95 |
| CMY-42                   | 1 | 1 | | | | | | | |
| CMY-146                  | | | | | | | | | |
| DHA-1                    | 1 | 1 | | | | | | | |
| ESBL + narrow-spectrum OXA (n = 83) | 1 | 8 | 48 | 18 | 1 | 1 | 1 | 78 | 96 |
| CTX-M-15 + OXA-1         | | | | | | | | | |
| CTX-M-15 + OXA-10        | | | | | | | | | |
| CTX-M-14 + OXA-1         | | | | | | | | | |
| CTX-M-3 + OXA-1          | | | | | | | | | |
| SHV-12 + OXA-9           | | | | | | | | | |
| ESBL + AmpC (n = 4)      | | | | | | | | | |
| CTX-M-55 + CMY-2         | | | | | | | | | |
| CTX-M-15 + CMY-138       | | | | | | | | | |
| ESBL + AmpC + narrow-spectrum OXA (n = 2) | | | | | | | | | |
| CTX-M-15 + CMY-2 + OXA-1 | | | | | | | | | |
| CTX-M-15 + CMY-138 + OXA-1 | | | | | | | | | |

### Table 2. Temocillin MIC frequency distribution for 42 K. pneumoniae bloodstream isolates according to β-lactamase type

| Organism characteristics | Number of isolates with MIC (mg/L): ≤2 | 4 | 8 | 16 | 32 | 64 | ≥128 | Total no. | Susceptible, increased exposure (%) EUCAST clinical breakpoint |
|--------------------------|----------------------------------------|---|---|---|----|----|------|-----------|---------------------------------------------------------------|
| All organisms            | 7 | 20 | 11 | 2 | 2 | 0 | 0 | 42 | 95 |
| No ESBL, AmpC or narrow-spectrum OXA ESBL only (n = 23) | 1 | | | | | | | | |
| CTX-M-3                  | 1 | 1 | | | | | | | 100 |
| CTX-M-14                 | 1 | 2 | | | | | | | 100 |
| CTX-M-15                 | 2 | 12 | 3 | 1 | | | | 18 | 94 |
| AmpC only (n = 1)        | 1 | | | | | | | | 100 |
| DHA-1                    | | | | | | | | | |
| ESBL + narrow-spectrum OXA (n = 15) | 3 | 5 | 4 | 2 | 1 | | | 15 | 93 |
| CTX-M-15 + OXA-1         | | | | | | | | | |
| ESBL + AmpC (n = 2)      | | | | | | | | | |
| CTX-M-14 + DHA-1         | 1 | | | | | | | | 100 |
| SHV-106 + DHA-1          | | | | | | | | | |

Temocillin activity in multi-resistant Gram negatives
Pseudomonas aeruginosa identified the role of the MexAB-OprM efflux system, as well as OpdK or OpdF anion-specific porin expression. Overall, favourable susceptibility results have been seen for UTI, with more variable results for systemic infection. This may reflect the decision by EUCAST to apply current species-related breakpoints to isolates from patients with urinary tract infection only.

Favourable activity of temocillin against an ESBL CTX-M-15 E. coli in a murine UTI model has been shown. Temocillin given at standard doses worked well against E. coli strains with an MIC of 16 mg/L or less. There remains limited data on the clinical effectiveness of temocillin in the treatment of infections due to MDR GNB. A study examining 92 infection episodes due to ESBL- and AmpC producers demonstrated clinical cure and microbiological cure rates of 86% and 84%, respectively, with use of temocillin. Similar results were observed in a small case series. Temocillin may also have a more favourable effect on the gut microbiome. Compared with ceftiraxone, temocillin did not promote expansion of ESBL-producing E. coli in faeces of colonized mice.

Key data on the use of temocillin remain unknown. Further in vitro and animal model work needs to be performed to better understand the pharmacokinetic and pharmacodynamic properties of the drug. Indeed, clinical data including outcomes with temocillin use will also better inform appropriate clinical breakpoints. Currently there are a few small registered clinical studies either in the recruitment or completion phases comparing temocillin with a carbapenem for treatment of infection due to ESBL- and/or AmpC-producing organisms, including the TEMO-CARB (NCT03543436), TEMO-BLSE (NCT04671290) and TEMO-ESBL (NCT02681263) trials.

**Conclusions**

Temocillin demonstrated favourable in vitro activity against ESBL- and AmpC-producing Enterobacteriales bloodstream isolates obtained from a clinical trial. Summary MIC values were obtained and indicated an MIC\textsubscript{50} of 8 mg/L and an MIC\textsubscript{90} of 16 mg/L (range ≤2 to ≥128 mg/L). Temocillin may be an appropriate carbapenem-sparing antibiotic, however, the results of

---

**Figure 1.** Temocillin MIC values determined by broth microdilution (BMD) of 317 E. coli and K. pneumoniae bloodstream isolates by (a) species, (b) ESBL, (c) AmpC β-lactamase, and (d) narrow-spectrum OXA β-lactamase.

*E. coli* and *K. pneumoniae* bloodstream isolates by (a) species, (b) ESBL, (c) AmpC β-lactamase, and (d) narrow-spectrum OXA β-lactamase.
well-designed clinical trials are awaited to determine its utility in clinical practice.

Acknowledgements
We would like to thank Av/Prof Scott Beatson, Dr Leah Roberts, and Prof Mark Schembri for assistance with whole genome sequencing.

Funding
This study was supported by internal funding.

Transparency declarations
D.L.P. has received funding from AstraZeneca, Pfizer, Shionogi, Spero Therapeutics, Leo Pharmaceuticals, Bayer, GlaxoSmithKline (GSK), Cubist, Entasis, Sumitomo, QPex, Venatorx, BioMerieux and Accelerate; reports board membership from Entasis, Qpex, Merck, Shionogi, Achaogen, AstraZeneca, Leo Pharmaceuticals, Bayer, GSK, Cubist, Venatorx, and Accelerate; reports grants/grants pending from Shionogi and Merck; and board membership from Entasis, Qpex, Merck, Shionogi, Achaogen, Entasis, Sumitomo, QPex, Venatorx, BioMerieux and Accelerate; reports grants/grants pending from Shionogi and Merck; and Kuch A, Zieniuk B, Zabicka D, et al. Activity of temocillin against ESBL-, AmpC-, and/or KPC-producing Enterobacteriaceae isolated in Poland. J Antimicrob Chemother 2018; 73: 634–42.

11 International Organization for Standardization. Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices — Part 1: broth micro-diffusion reference method for testing in vitro activity of antimicrobial agents against rapidly growing aerobic bacteria involved in infectious diseases (ISO 20776-1:2019). 2019. https://www.iso.org/standard/70464.html.

12 EUCAST. Clinical breakpoints and dosing of antibiotics. http://www.eucast.org/clinical_breakpoints/.

13 Andrews JM. The development of the BSAC standardized method of disc diffusion testing. J Antimicrob Chemother 2001; 48 Suppl 1: 29–42.

14 Kuch A, Zieniuk B, Zabicka D, et al. Activity of temocillin against ESBL-, AmpC-, and/or KPC-producing Enterobacteriaceae isolated in Poland. Eur J Clin Microbiol Infect Dis 2020; 39: 1185–91.

15 Ip M, Lai CK, Fung KSC, et al. Activity of temocillin and 15 other agents, including fosfomycin and colistin, against Enterobacteriaceae in Hong Kong. Eur J Clin Microbiol Infect Dis 2017; 36: 2491–4.

16 Livermore DM, Hope R, Fagan EJ, et al. Activity of temocillin against prevalent ESBL- and AmpC-producing Enterobacteriaceae from south-east England. J Antimicrob Chemother 2006; 57: 1012–4.

17 Zykov IN, Sundsfjord A, Småbrekke L, et al. The antimicrobial activity of mecillinam, nitrofurantoin, temocillin and fosfomycin and comparative analysis of resistance patterns in a nationwide collection of ESBL-producing Escherichia coli in Norway 2010–2011. Infect Dis (Lond) 2016; 48: 99–107.

18 Farfour E, Si Larbi AG, Cattoir V, et al. Temocillin susceptibility among Enterobacteriaceae strains recovered from blood culture in France. Diagn Microbiol Infect Dis 2021; 100: 115368.

19Chalhoub H, Pletzer D, Weingart H, et al. Mechanisms of intrinsic resistance and acquired susceptibility of Pseudomonas aeruginosa isolated from cystic fibrosis patients to temocillin, a revived antibiotic. Sci Rep 2017; 7: 40208.

20Soubirau JF, Rossi B, Couffignal C, et al. Activity of temocillin in a murine model of urinary tract infection due to Escherichia coli producing or not producing the ESBL CTX-M-15. J Antimicrob Chemother 2015; 70: 1466–72.

21Balakrishnan I, Awad-El-Kariem FM, Aali A, et al. Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and/or derepressed AmpC β-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother 2011; 66: 2628–31.

22 Gupta ND, Smith RE, Balakrishnan I. Clinical efficacy of temocillin. J Antimicrob Chemother 2009; 64: 431–3.

23 Chenouard R, Mahieu R, Luque Paz D, et al. Impact of ceftriaxone and temocillin on fecal abundance of extended-spectrum β-lactamase producing Escherichia coli in a mouse model. PLoS One 2021; 16: e0248177.